Bavarian Nordic
bavarian-nordic.comTotal trials
57
Active
6
Phase 3
14
Total enrollment
55,442
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 5 of 5 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| CHIKV VLP vaccine | — | — | — | — | — | 2 | |
| CHIKV VLP vaccine booster | — | — | — | — | — | 1 | |
| MVA-BN | — | — | — | — | 3 | ||
| Jynneos | — | — | — | — | — | 1 | |
| MVA-BN-WEV | — | — | — | — | — | 1 |
Next readouts
- 2026-05-01
- 2026-11-30
- 2027-02
- 2028-04
- 2028-12
- 2030-05
Top conditions
- Smallpox10
- HIV Infections5
- Chikungunya Virus5
- Respiratory Syncytial Virus Infections4
- Cholera4
- Chikungunya Virus Infection2
- Chordoma2
- Monkeypox (Mpox)2
Frequently asked questions about Bavarian Nordic
- How many clinical trials does Bavarian Nordic have on ClinicalTrials.gov?
- Bavarian Nordic is listed as the lead sponsor on 57 clinical trials in ClinicalTrials.gov, 6 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Bavarian Nordic's trials are in Phase 3?
- 14 of Bavarian Nordic's trials are in Phase 3, spread across 5 active drug programs.
- What therapeutic areas does Bavarian Nordic focus on?
- Bavarian Nordic's most-studied conditions on ClinicalTrials.gov are Smallpox, HIV Infections, Chikungunya Virus, Respiratory Syncytial Virus Infections, Cholera.
- When are Bavarian Nordic's next clinical trial readouts?
- Bavarian Nordic has 6 upcoming primary-completion readouts tracked here; the soonest is “Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections”, expected around 2026-05-01.